Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:850-855

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moliterno, D. J.
Right arrow Articles by Hobbs, H. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moliterno, D. J.
Right arrow Articles by Hobbs, H. H.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:850-855.)
© 1995 American Heart Association, Inc.

Articles

No Association Between Plasma Lipoprotein(a) Concentrations and the Presence or Absence of Coronary Atherosclerosis in African-Americans

David J. Moliterno; Eero V. Jokinen; André R. Miserez; Richard A. Lange; John E. Willard; Eric Boerwinkle; L. David Hillis; Helen H. Hobbs

From the Department of Cardiology, the Cleveland Clinic Foundation, Cleveland, Ohio (D.J.M.), the Departments of Internal Medicine and Molecular Genetics, University of Texas Southwestern Medical Center, and the Center for Demographics and Population Genetics, University of Texas Health Science Center (E.B.), Houston, Tex.

Correspondence to Dr Helen H. Hobbs, Department of Molecular Genetics, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75235-9046.


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Abstract Elevated plasma concentrations of lipoprotein(a) [Lp(a)] are associated with coronary atherosclerosis in Caucasians. Although African-Americans have a higher median plasma Lp(a) concentration than Caucasians, they do not have a greater incidence of coronary atherosclerosis. This study was performed to determine whether the plasma concentration of Lp(a) is associated with coronary atherosclerosis in African-Americans. The fasting plasma concentrations of Lp(a) and lipoproteins were measured in 140 African-American subjects (62 men, 78 women, aged 31 to 80 years) 18±16 months (mean±SD) after they underwent coronary angiography: 72 had angiographically normal coronary arteries and 68 had >70% luminal diameter narrowing of one or more major epicardial coronary arteries. The groups were similar in age, sex, and other risk factors for atherosclerosis. The subjects with coronary artery disease had higher plasma concentrations of total cholesterol, triglycerides, and VLDL and LDL cholesterol (P=.04) and lower concentrations of HDL cholesterol (P=.0001) than subjects without coronary artery disease, but there was no significant difference in the plasma concentration of Lp(a). The distribution of apolipoprotein(a) alleles by size was also not significantly different between the two groups. These results suggest that the plasma concentration of Lp(a) is not an independent risk factor for coronary artery disease in African-Americans.


Key Words: lipoprotein(a) • African-Americans • plasminogen


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Lipoprotein(a) [Lp(a)] is a cholesterol ester–rich lipoprotein composed of an LDL particle and a large glycoprotein, apolipoprotein(a) [apo(a)].1 2 Apo(a) is highly variable in size because of length polymorphism in the apo(a) gene.1 3 Apo(a) alleles differ in the number of a tandemly repeated sequence that encodes a protein motif resembling the kringle 4 of plasminogen. Plasma Lp(a) concentrations are largely determined by sequence differences at, or closely linked to, the apo(a) locus4 and tend to be inversely related to the number of kringle 4–encoding sequences in the apo(a) gene.1 3

In a given individual, the plasma concentration of Lp(a) is remarkably constant and relatively uninfluenced by age and dietary intake.5 In Caucasians and Orientals the population distribution of plasma Lp(a) levels is highly skewed, so that most individuals have low circulating levels of plasma Lp(a).1 5 6 7 In these populations, high plasma concentrations of Lp(a) (more than 20 to 30 mg/dL) tend to be associated with an increase in the prevalence and severity of coronary artery disease (CAD).7 8 9 10 In contrast, the population distribution of plasma Lp(a) levels in Africans and African-Americans is more symmetric; these populations therefore have a mean plasma concentration of Lp(a) two times higher than that in either Caucasians or Orientals.1 11 12 13 14 15 16 17 Despite having significantly higher plasma Lp(a) concentrations, African-Americans have a similar or lower prevalence of ischemic heart disease than Caucasians.18 19 20 21 22

Only one study has examined the relationship between plasma Lp(a) concentrations and CAD in African-Americans with angiographically defined coronary arteries.23 In that study, the plasma Lp(a) levels of 32 African-Americans without CAD were compared with those in 79 subjects with CAD. The plasma concentrations of Lp(a) tended to be higher in the subjects with CAD, but the difference was not statistically significant.23 To investigate further whether high plasma concentrations of Lp(a) are associated with atherosclerotic CAD in African-Americans, plasma Lp(a) levels and size distribution of apo(a) alleles were compared in African-Americans with angiographically normal coronary arteries or significant CAD.


*    Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Methods
down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Patient Population
A total of 364 African-American patients underwent coronary angiography at Parkland Memorial Hospital in Dallas, Tex, between January 1988 and December 1991. All cineangiograms were reviewed by two experienced angiographers and categorized as showing (1) normal coronary arteries (<10% diameter stenosis), (2) minor CAD (>=10% to <=70% diameter stenosis), or (3) significant coronary atherosclerosis (>70% luminal diameter narrowing of one or more major epicardial coronary arteries). All patients with 10% to 70% diameter stenosis of a single epicardial vessel were then excluded, as were those with a confounding chronic illness such as end-stage renal disease, steroid-treated immunologic disorder, or poorly controlled diabetes mellitus (n=49). Therefore, 315 subjects (237 with and 78 without CAD) were eligible for enrollment. Efforts were made to contact all 315 subjects. Twenty-six could not be located (23 with CAD and 3 without CAD) and 7 had died (all with CAD). Of the remaining 282 subjects, the 140 who were scheduled for routine outpatient follow-up between December 1991 and February 1992 were contacted before the clinic visit, and all agreed to participate in the study. Of these 140 (62 men and 78 women, aged 31 to 80 years), 72 had angiographically normal coronary arteries (Group I) and 68 had CAD (Group II). The study protocol was approved by the Human Subjects Review Committee of The University of Texas Southwestern Medical Center, and all subjects gave written informed consent.

Variables Assessed
The medical record of each patient was reviewed, and each patient was interviewed to determine the presence of risk factors for atherosclerotic cardiovascular disease. All medications were noted. Fasting venous blood samples were obtained between 8:00 AM and 10:00 AM in tubes containing EDTA or buffered citrate. The blood was maintained at 4°C, and the plasma was separated by centrifugation (2000g for 20 minutes) within 1 hour. The time interval from catheterization to procurement of blood was 18±16 months (mean±SD). No blood was sampled from subjects within 6 months of having unstable angina, myocardial infarction, or bypass surgery.

Plasma lipoprotein cholesterol concentrations were measured according to the procedures of the Lipid Research Clinics.24 Total plasma cholesterol and triglycerides were measured with enzymatic assay kits (Boehringer Mannheim Biochemicals and Sigma Chemical Co). Fibrinogen was measured by a standardized polymerization method (Dade Diagnostica). The plasminogen assay was performed with samples incubated in an excess of streptokinase, and the plasminlike activity was measured in the presence of a chromogenic substrate (Kabi Diagnostica, Helena Laboratories). The plasma concentrations of Lp(a) were measured by use of a sandwich enzyme-linked immunosorbent assay (GeneScreen Laboratories), according to the method of Menzel et al25 and as previously described.3 In brief, the capture antibody was an affinity-purified polyclonal rabbit anti-human apo(a) antibody and the detection antibody was a mouse monoclonal anti-apo(a)–specific antibody (IgG-1A2). The epitope for this antibody resides within the kringle 4 repeat (written communication, Gerd Utermann, MD, 1994). The standard used in the assay was supplied by Immuno AG and had a concentration of 52.4 mg/dL. Two assays were performed in duplicate on plasma samples from each subject, and the average of the concentrations was used for these analyses. The rank correlation coefficient between the two Lp(a) measurements was 0.96.

Immunoblot Analysis of Apo(a) Isoforms
Apo(a) isoform analysis was performed by use of a modification of the immunoblotting method of Kamboh et al26 as previously described.24 The isoforms were designated according to the total number of kringle 4 repeats contained within their sequence [apo(a)K-12 to apo(a)K-51], as determined by relative comigration with previously characterized standards.27 The kringle 4–encoding region of the apo(a) gene was analyzed directly by pulsed-field gel analysis in the subset of individuals in whom no apo(a) isoform (one subject in Group I and one in Group II) or only a single apo(a) isoform (18 subjects in Group I and 25 in Group II) was visible by immunoblotting.

Pulsed-Field Gel Electrophoresis and Genomic Blotting
High–molecular weight genomic DNA was isolated from mononuclear cells obtained from 16 mL of blood3 and subjected to digestion with HpaI. The DNA fragments were size fractionated using pulsed-field gel electrophoresis, and genomic blotting was performed with an apo(a)-specific probe as previously described.24 The apo(a) alleles were sized according to their relative migration to known standards and designated according to the total number of kringle 4–encoding sequences in the apo(a) gene.27 In three subjects without CAD, no high–molecular weight genomic DNA was available for performance of the pulsed-field gel analysis, so their data are not included in the apo(a) allele frequency data.

Statistical Methodology
All data are reported as the median and mean±SD. Subjects with angiographically normal coronary arteries (Group I) were compared with those with CAD (Group II) by use of a Mann-Whitney rank-sum test for continuous variables28 and a {chi}2 test for categorical variables. Because of the large number of apo(a) alleles, traditional {chi}2 tests of independence were inappropriate for examination of the relationship between CAD and apo(a) alleles. Comparison of apo(a) allele frequencies between groups was carried out using a Monte Carlo approximation to Fisher's exact test.29 The power of the Mann-Whitney rank-sum test was confirmed (calculated to be >85%) by use of the formulas provided by Noether.30 Stepwise logistic regression31 was performed to assess the ability to use a subject's plasma Lp(a) concentrations to determine the probability of his or her having CAD while other predictor variables were simultaneously considered. For all analyses, a value of P<.05 was considered significant. Following the suggestion of Rothman,32 we made no adjustments for multiple comparisons.


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 *Results
down arrowDiscussion
 down arrowReferences
 
The African-American subjects in Groups I and II were similar in age, sex, estrogen status for women, and the presence of other risk factors for atherosclerotic cardiovascular disease (Table 1Down). There was a high frequency of cardiac risk factors in both groups because people with multiple risk factors in this population are much more likely to obtain a cardiac catherization than those without such factors. More subjects with CAD were taking ß-blockers, aspirin, or hypolipidemic agents (Table 1Down). Among those with CAD, six were receiving lovastatin, one was receiving cholestyramine, and one was receiving gemfibrozil, whereas only one subject in the group with normal coronary arteries was receiving lovastatin. Bile acid resins, 3-hydroxy-3-methylglutaryl coenzyme A–reductase inhibitors, and gemfibrozil in the given doses do not significantly influence the plasma concentration of Lp(a).33 34


View this table:
[in this window]
[in a new window]
  		Table 1. Demographics of the Two Study Groups

The two groups had similar concentrations of fibrinogen and plasminogen but differed significantly with respect to plasma lipoprotein concentrations (Table 2Down). Despite there being a higher percentage of subjects taking lipid-lowering agents in Group II, these patients had significantly higher plasma concentrations of total cholesterol, triglycerides, VLDL cholesterol, and LDL cholesterol as well as lower plasma levels of HDL cholesterol. In contrast, there was no significant difference in the plasma concentrations of Lp(a) in the two groups: the median plasma Lp(a) concentrations were identical (42 mg/dL), and the mean plasma concentration of Lp(a) was 54±47 mg/dL for Group I patients and 52±38 mg/dL for Group II patients (P=.90). When data from only those not taking lipid-lowering medications were analyzed, plasma Lp(a) concentrations remained similar for the two groups (Table 3Down).


View this table:
[in this window]
[in a new window]
  		Table 2. Results of Plasma Assays for the Two Study Groups


View this table:
[in this window]
[in a new window]
  		Table 3. Subgroup Analysis of Plasma Lipoprotein(a) Levels

In subjects with and without angiographically significant CAD, the distribution of plasma Lp(a) levels was similar (Fig 1Down). The frequency of low and high plasma Lp(a) levels (defined as levels below or above the sample median, respectively) was not significantly different in the two groups ({chi}2=0.03, 1 df; P=.87); 35 Group I subjects (49%) and 34 Group II subjects (50%) had Lp(a) levels that were higher than the mean. With stepwise logistic regression analyses, use of plasma Lp(a) concentrations did not improve the ability to predict the probability of a subject's having CAD (data not shown). The significant predictors of CAD in this sample of African-Americans were age, total cholesterol, and HDL cholesterol. When these variables were considered, plasma Lp(a) concentrations did not contribute to the prediction of a patient's having CAD (P=.72).



View larger version (21K):
[in this window]
[in a new window]
  		Figure 1. The distribution of plasma lipoprotein(a) levels in African-American subjects with (solid bars) and without (open bars) coronary artery disease (CAD).

Previous studies have suggested that Lp(a) may interact with other factors, such as plasma LDL cholesterol, to increase the risk of CAD.13 35 To investigate further the apparent lack of association between plasma Lp(a) concentration and the presence of CAD in African-Americans, the distribution of Lp(a) was compared in subgroups of individuals with and without angiographically significant CAD (Table 3Up). There was no difference in plasma Lp(a) levels when men and women were analyzed separately or in subjects with elevated plasma LDL cholesterol, triglycerides, plasminogen, or fibrinogen or reduced plasma concentrations of HDL cholesterol. In addition, plasma Lp(a) levels were similar in smokers and nonsmokers, subjects with and without hypertension or diabetes (data not shown), and those receiving and not receiving hypolipidemic medications. Postmenopausal women had notably higher plasma levels of Lp(a) than premenopausal women regardless of CAD status (71 mg/dL and 43 mg/dL, respectively).

To determine whether there were differences in the size distribution of apo(a) alleles in the two groups, the apo(a) genotypes were determined by apo(a) isoform immunoblotting and by pulsed-field gel electrophoresis and genomic blotting of the apo(a) gene. Previous studies have demonstrated a direct relationship between apo(a) gene length and apo(a) isoform size,3 so in subjects in whom both apo(a) isoforms were visible the apo(a) alleles were determined by immunoblotting alone. The kringle 4–encoding region of the apo(a) gene was analyzed directly by pulsed-field gel analysis in samples in which no apo(a) isoform or only a single apo(a) isoform was visible by immunoblotting. The length distribution of apo(a) alleles is shown in Fig 2Down. The number of kringle 4 repeats in the apo(a) alleles ranged from 12 to 38 in those with CAD (Fig 2ADown) and from 12 to 43 in those without CAD (Fig 2BDown). As expected, based on the sample size and the large number of alleles, there were some differences in the relative frequencies of selected alleles. However, there was no significant difference in the overall apo(a) allele size distributions between the two groups (P=.78).



View larger version (15K):
[in this window]
[in a new window]
  		Figure 2. The distribution of apolipoprotein(a) [apo(a)] alleles in subjects with angiographically significant coronary artery disease (CAD) (A) or normal coronary arteries (B). The total number of apo(a) alleles analyzed is given. Data from three subjects in the CAD group are not included in the analysis because their genomic DNA was not available. The apo(a) alleles are classified on the basis of the total number of kringle 4 repeats in the apo(a) gene, as reflected by the size of the apo(a) isoforms on immunoblotting or the size of an HpaI restriction fragment, which contains the kringle 4 repeats, that varies between apo(a) alleles, as previously described.27


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 *Discussion
down arrowReferences
 
In this study, plasma Lp(a) concentrations and the distributions of apo(a) allele sizes were compared in African-Americans with and without angiographically significant CAD. There was no significant difference in the levels of plasma Lp(a) or the distribution of apo(a) isoform sizes between the two groups.

Two previously published studies have examined the relationship between plasma Lp(a) levels and CAD in African-Americans, and their results are consistent with our findings. In the Bogalusa Heart Study, plasma Lp(a) concentrations were measured in Caucasian and African-American children with and without a parental history of myocardial infarction.36 37 Caucasian children with a parental history of myocardial infarction had a significantly higher plasma level of Lp(a) than those without a parental history of ischemic cardiac events.37 In contrast, in the African-American group, there was no significant difference between the plasma concentrations of Lp(a) of children with and without a parental history of myocardial infarction. A cross-sectional study of the plasma Lp(a) concentrations in African-Americans from a northern US urban population found no significant difference in plasma Lp(a) levels in those with and without angiographically defined CAD.23

In this study, there were more postmenopausal women in the group without CAD (n=33) than in the group with CAD (n=20), but the numbers of estrogen-positive women (ie, premenopausal women and postmenopausal women who were taking estrogen) and estrogen-negative women (ie, postmenopausal women not taking estrogen) were not significantly different (Table 1Up). In Caucasians, postmenopausal women have an {approx}10% to 50% increase in plasma Lp(a) levels compared with premenopausal women.38 39 The postmenopausal women in this study who were not on estrogen supplementation had significantly higher median plasma Lp(a) levels than their premenopausal counterparts (Table 3Up). In Caucasians, estrogen therapy is associated with a decrease in plasma Lp(a) levels in both women and men.40 41 42 The number of postmenopausal women receiving estrogen replacement in this study is too small for the effect of estrogen on plasma Lp(a) levels to be evaluated. No study to date has examined the effect of estrogen replacement on plasma Lp(a) levels in African-Americans.

Our study has certain limitations. First, it is a retrospective study of African-Americans referred for coronary angiography over a 4-year period. Of the 282 subjects eligible for study, blood was collected from an unselected sample of 140 who had a follow-up visit planned during the 3-month study enrollment. The groups were well matched for age, sex, and coronary risk factors. We cannot exclude the possibility that our results would have been different if all 282 subjects had been studied. Second, because many of our patients had risk factors for atherosclerotic cardiovascular disease, we cannot assess the association of plasma Lp(a) with CAD in African-Americans without other risk factors. Finally, we excluded patients with mild to moderate (10% to 70%) coronary arterial stenoses. Thus, we cannot comment on the possible, although unlikely, association of Lp(a) with intermediate CAD.

However, our study has certain strengths. It is the largest published study assessing the association of plasma Lp(a) concentrations with angiographically proven CAD in African-Americans, and it is the only study to assess the distribution of apo(a) allele sizes in African-Americans with and without CAD. Moreover, the patient cohorts were angiographically distinct in that only those with a coronary lumen diameter stenosis of less than 10% or more than 70% were studied.

The lack of association between plasma concentrations of Lp(a) and CAD may reflect unidentified (genetic or environmental) differences between the Caucasian and African-American populations. African-Americans may be protected from the atherogenic effect of high plasma concentrations of Lp(a) by counterbalancing factors. For example, compared with Caucasians, African-Americans (especially men) have higher plasma concentrations of HDL cholesterol and lower concentrations of LDL cholesterol,43 44 which may attenuate the atherosclerotic potential of Lp(a). In addition, studies have suggested that African-Americans have a greater sensitivity to tissue plasminogen activation than do Caucasians.45 This is of particular interest in light of numerous in vitro studies that have demonstrated that high concentrations of Lp(a) can interfere with plasmin generation.2

The apo(a) glycoprotein is highly polymorphic in length; a total of 34 differently sized apo(a) isoforms can be distinguished by use of agarose gel electrophoresis and immunoblotting.27 46 Differently sized apo(a) alleles may result in variability in the presence or number of atherogenic-promoting sequences. Some but not all studies that have compared the frequency distribution of apo(a) isoforms in Caucasians and Orientals with and without CAD have found that the smaller apo(a) isoforms are more frequent in subjects with CAD.17 46 47 48 Importantly, in our study of African-Americans, we found no significant difference in the distribution of apo(a) alleles by size in those with or without CAD. However, our analysis does not exclude the possibility that the apo(a) alleles in the African-American population (irrespective of their size) may differ in sequence from those in other populations. Apo(a) sequence(s) that are responsible for mediating the atherogenic or thrombogenic effects of Lp(a) may not be as prevalent in the African-American population.

The atherogenic potential of Lp(a) may differ between African-Americans and other populations. In Caucasians and Orientals, most cross-sectional studies and some49 50 51 but not all52 53 54 prospective studies have found that high plasma levels of Lp(a) are associated with CAD (for review, see Reference 5555 ). The reason for the lack of an association between elevated plasma Lp(a) levels and cardiac events in three prospective studies52 53 54 is not known, but it may be due to methodological problems associated with measuring plasma Lp(a) levels after prolonged storage. Alternatively, these discrepant results, together with our finding of no association between plasma Lp(a) levels and the presence or absence of CAD in African-Americans, may suggest that elevated plasma Lp(a) levels are not uniformly associated with an increased cardiac risk.


*    Acknowledgments
 
This work was supported in part by grants from the Perot Family Foundation and Bristol-Myers Squibb and by National Institutes of Health grants HL-47619, HL-20948, and HL-40613. Dr Jokinen is a recipient of an award from the Paulo and Ella och George Ehnroot Foundations. Dr Miserez is supported by the Swiss Foundation for Medical-Biological Grants. Dr Boerwinkle is the recipient of a Research Career Development Award from the National Institutes of Health. Dr Boerwinkle and Dr Hobbs are Established Investigators of the American Heart Association. We acknowledge the assistance of Scott Grundy, MD, PhD, for performing the lipid assays and Joy Ashcraft, Anne Kim, and Susanne Weant for performing the assays of plasminogen and fibrinogen.

Received February 12, 1995; accepted March 20, 1995.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 up arrowDiscussion
 *References
 

  1. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246:904-910. [Abstract/Free Full Text]
  2. Liu A, Lawn RM. Lipoprotein(a) and atherogenesis. Trends Cardiovasc Med. 1994;4:40-44.
  3. Lackner C, Boerwinkle E, Leffert C, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest. 1991;87:2077-2086.
  4. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52-60.
  5. Albers JJ, Marcovina SM, Lodge MS. The unique lipoprotein(a): properties and immunochemical measurement. Clin Chem. 1990;36:2019-2026. [Abstract/Free Full Text]
  6. Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Csaszar A, Boerwinkle E, Utermann G. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86:607-614. [Medline] [Order article via Infotrieve]
  7. Sandholzer C, Boerwinkle E, Saha N, Tong MC, Utermann G. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest. 1992;89:1040-1046.
  8. Rhoads GG, Dahlèn GH, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986;256:2540-2544. [Abstract]
  9. Dahlèn GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758-765. [Abstract/Free Full Text]
  10. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H, Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: dependence on serum LDL levels. Atherosclerosis. 1986;62:249-257. [Medline] [Order article via Infotrieve]
  11. Guyton JR, Dahlèn GH, Patsch W, Kautz JA, Gotto AM Jr. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis. 1985;5:265-272. [Abstract/Free Full Text]
  12. Parra H, Luyeye I, Bouramoue C, Demarquilly C, Fruchart JC. Black-white differences in serum Lp(a) lipoprotein levels. Clin Chim Acta. 1987;167:27-31.
  13. Helmhold M, Bigge J, Muche R, Mainoo J, Thiery J, Seidel D, Armstrong VW. Contribution of the apo(a) phenotype to plasma Lp(a) concentrations shows considerable ethnic variation. J Lipid Res. 1991;32:1919-1928. [Abstract]
  14. Gaw A, Boerwinkle E, Cohen JC, Hobbs HH. Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups, evidence for no common "null" allele at the apo(a) locus. J Clin Invest. 1994;93:2526-2534.
  15. Cobbaert C, Kesteloot H. Serum lipoprotein(a) levels in racially different populations. Am J Epidemiol. 1992;136:441-449. [Abstract/Free Full Text]
  16. Heyden S, Eckardstein AV, Schulte H, Schneider K, Assmann G. Raised lipoprotein(a) in hypercholesterolemic black students compared to age-matched whites in North and South Carolina. Int J Epidemiol. 1994;23:301-306. [Abstract/Free Full Text]
  17. Marcovina SM, Albers JJ, Jacobs DR Jr, Perkins LL, Lewis CE, Howard BV, Savage P. Lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in Caucasians and African Americans: the CARDIA study. Arterioscler Thromb. 1993;13:1037-1045. [Abstract/Free Full Text]
  18. National Center for Health Statistics. Vital and Health Statistics, No. 181. Hyattsville, MD: US Dept of Health and Human Services; 1990. DHHS Pub No. (PHS) 92-1509.
  19. Kautz JA, Bradshaw BA, Fonner E Jr. Trends in cardiovascular mortality in Spanish-surnamed, other white, and black persons in Texas, 1970-1975. Circulation. 1981;64:730-735. [Abstract/Free Full Text]
  20. Gillum RF. Coronary heart disease in black populations, I: mortality and morbidity. Am Heart J. 1982;104:839-851. [Medline] [Order article via Infotrieve]
  21. Cassel J, Heyden S, Bartel AG. Incidence of coronary heart disease by ethnic group, social class, and sex. Arch Intern Med. 1971;128:901-906. [Medline] [Order article via Infotrieve]
  22. Keil JE, Sutherland SE, Knapp RG, Lackland DT, Gazes PC, Tyroler HA. Mortality rates and risk factors from coronary disease in black as compared with white men and women. N Engl J Med. 1993;329:73-78. [Abstract/Free Full Text]
  23. Sorrentino MJ, Vielhauer C, Eisenbart JD, Fless GM, Scanu AM, Feldman T. Plasma lipoprotein(a) concentration and coronary artery disease in black patients compared with white patients. Am J Med. 1992;93:658-662. [Medline] [Order article via Infotrieve]
  24. Lipid Research Clinics Program. Lipid and Lipoprotein Analysis: Manual of Laboratory Operations. Washington, DC: US Dept of Health, Education, and Welfare; 1982. Pub. No. NIH/75-628.
  25. Menzel HJ, Dieplinger H, Lackner C, Hoppichler F, Lloyd JK, Muller DR, Labeur C, Talmud PJ, Utermann G. Abetalipoproteinemia with an apoB-100-lipoprotein(a) glycoprotein complex in plasma. J Biol Chem. 1990;265:981-986. [Abstract/Free Full Text]
  26. Kamboh MI, Ferrell RE, Kottke BA. Expressed hypervariable polymorphism of apolipoprotein(a). Am J Hum Genet. 1991;49:1063-1074. [Medline] [Order article via Infotrieve]
  27. Lackner C, Cohen J, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet. 1993;2:933-940. [Abstract/Free Full Text]
  28. Conover WJ. Practical Non-Parametric Statistics. New York, NY: John Wiley & Sons, Inc; 1980:215-237.
  29. Guo WS, Thompson EA. Monte Carlo Estimation of P-Values for Sparse Contingency Tables: Technical Report #187. Seattle, Wash: University of Washington; 1987.
  30. Noether GE. Sample size determination for some common nonparametric tests. J Am Stat Assoc. 1987;82:645-647.
  31. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons; 1989:106-112.
  32. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43-46. [Medline] [Order article via Infotrieve]
  33. Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). Atherosclerosis. 1982;44:61-71. [Medline] [Order article via Infotrieve]
  34. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 1989;80:1313-1319. [Abstract/Free Full Text]
  35. Utermann G, Hoppichler F, Dieplinger H, Seed M, Thompson G, Boerwinkle E. Defects in the low density lipoprotein receptor gene affect lipoprotein(a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci U S A. 1989;86:4171-4174. [Abstract/Free Full Text]
  36. Srinivasan SR, Frerichs RR, Webber LS, Berenson GS. Serum lipoprotein profile in children from a biracial community: the Bogalusa Heart Study. Circulation. 1976;54:309-318. [Abstract/Free Full Text]
  37. Srinivasan SR, Dahlèn GH, Jarpa RA, Webber LS, Berenson GS. Racial (black-white) differences in serum lipoprotein(a) distribution and its relation to parental myocardial infarction in children. Circulation. 1991;84:160-167. [Abstract/Free Full Text]
  38. Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PWF, Castelli WP, Shaefer EJ. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels: The Framingham Offspring Study. Circulation. 1993;87:1135-1141. [Abstract/Free Full Text]
  39. Heinrich J, Sandkamp M, Kokott R, Schulte H, Assmann G. Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem. 1991;37:1950-1954. [Abstract/Free Full Text]
  40. Henriksson P, Angelin B, Berglund L. Hormonal regulation of serum Lp(a) levels. J Clin Invest. 1992;89:1166-1171.
  41. Soma M, Osnago-Gadda I, Paoletti R, Fumagalli R, Morrisett J, Meschia M, Crosignani P. The lowering of lipoprotein(a) by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med. 1993;153:1462-1468. [Abstract]
  42. Nabulsi A, Folsom A, White A, Patsch W, Heiss G, Wu K, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328:1069-1075. [Abstract/Free Full Text]
  43. Tyroler HA, Heiss G, Schonfeld G, Cooper G, Heyden S, Hames CG. Apolipoprotein A-I, A-II, and C-II in African American and Caucasian residents of Evans County. Circulation. 1980;62:249-254. [Abstract/Free Full Text]
  44. Morrison JA, de Groot I, Kelly KA, Mellies MJ, Khoury P, Edwards BK, Lewis D, Lewis A, Fiorelli M, Heiss G, Tyroler HA, Glueck CJ. Black-white differences in plasma lipids and lipoproteins in adults: the Cincinnati Lipid Research Clinic population study. Prev Med. 1979;8:34-39. [Medline] [Order article via Infotrieve]
  45. Sane DC, Stump DC, Topol EJ, Sigmon KN, Clair WK, Kereiakes DJ, George BS, Stoddard MF, Bates ER, Stack RS, Califf RM. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group: racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Circulation. 1991;83:170-175. [Abstract/Free Full Text]
  46. Marcovina SM, Zhang ZH, Gaur VP, Albers JJ. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun. 1993;191:1192-1196. [Medline] [Order article via Infotrieve]
  47. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thomson GR, Boerwinkle E, Utermann G. Relation of serum lipoprotein(a) concentration and lipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990;322:1494-1499. [Abstract]
  48. Abe A, Noma A, Lee YJ, Yamaguchi H. Studies on apolipoprotein(a) phenotypes, part 2: phenotype frequencies and Lp(a) concentrations in different phenotypes in patients with angiograpically defined coronary artery disease. Atherosclerosis. 1992;96:9-15. [Medline] [Order article via Infotrieve]
  49. Rosengran A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ. 1990;301:1248-1251.
  50. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen risk incidence and prevalence study (GRIPS). Eur J Clin Invest. 1994,24:444-453.
  51. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis E, Abolafia JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men. JAMA. 1994;271:999-1003. [Abstract]
  52. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270:2195-2199. [Abstract]
  53. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Mänttäri M, Manninen V, Huttunen JK. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991;89:59-67. [Medline] [Order article via Infotrieve]
  54. Alfthan G, Pekkanen J, Jauhiainen M, Karvonen M, Tuoilehto J, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9-19. [Medline] [Order article via Infotrieve]
  55. Rader DJ, Hoeg JM, Brewer HB. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med. 1994;120:1012-1025.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am J EpidemiolHome page
K. A. Volcik, R. A. Barkley, R. G. Hutchinson, T. H. Mosley, G. Heiss, A. R. Sharrett, C. M. Ballantyne, and E. Boerwinkle
Apolipoprotein E Polymorphisms Predict Low Density Lipoprotein Cholesterol Levels and Carotid Artery Wall Thickness but Not Incident Coronary Heart Disease in 12,491 ARIC Study Participants
Am. J. Epidemiol., August 15, 2006; 164(4): 342 - 348.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. Guerra, Z. Yu, S. Marcovina, R. Peshock, J. C. Cohen, and H. H. Hobbs
Lipoprotein(a) and Apolipoprotein(a) Isoforms: No Association With Coronary Artery Calcification in The Dallas Heart Study
Circulation, March 29, 2005; 111(12): 1471 - 1479.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
L. Berglund and R. Ramakrishnan
Lipoprotein(a): An Elusive Cardiovascular Risk Factor
Arterioscler. Thromb. Vasc. Biol., December 1, 2004; 24(12): 2219 - 2226.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. A. Albert, J. Torres, R. J. Glynn, and P. M Ridker
Perspective on Selected Issues in Cardiovascular Disease Research With a Focus on Black Americans
Circulation, July 13, 2004; 110(2): e7 - e12.
[Full Text] [PDF]

Home page
 CirculationHome page
References
Circulation, December 17, 2002; 106(25): 3373 - 3421.
[Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
F. Paultre, C. H. Tuck, B. Boden-Albala, D. E. Kargman, E. Todd, J. Jones, M. C. Paik, R. L. Sacco, and L. Berglund
Relation of Apo(a) Size to Carotid Atherosclerosis in an Elderly Multiethnic Population
Arterioscler. Thromb. Vasc. Biol., January 1, 2002; 22(1): 141 - 146.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. Rubin, T. A. Pearson, R. G. Reed, and L. Berglund
Fluorescence-based, Nonradioactive Method for Efficient Detection of the Pentanucleotide Repeat (TTTTA)n Polymorphism in the Apolipoprotein(a) Gene
Clin. Chem., October 1, 2001; 47(10): 1758 - 1762.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
F. Paultre, T. A. Pearson, H. F. C. Weil, C. H. Tuck, M. Myerson, J. Rubin, C. K. Francis, H. F. Marx, E. F. Philbin, R. G. Reed, et al.
High Levels of Lp(a) With a Small Apo(a) Isoform Are Associated With Coronary Artery Disease in African American and White Men
Arterioscler. Thromb. Vasc. Biol., December 1, 2000; 20(12): 2619 - 2624.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. M. Grundy, R. Pasternak, P. Greenland, S. Smith Jr, and V. Fuster
Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology
J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1348 - 1359.
[Full Text] [PDF]

Home page
 CirculationHome page
S. M. Grundy, R. Pasternak, P. Greenland, S. Smith Jr, and V. Fuster
Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations : A Statement for Healthcare Professionals From the American Heart Association and the American College of Cardiology
Circulation, September 28, 1999; 100(13): 1481 - 1492.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
K. J. Harjai
Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen
Ann Intern Med, September 7, 1999; 131(5): 376 - 386.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P. Fontana, V. Mooser, P. Bovet, C. Shamlaye, B. Burnand, V. Lenain, S. M. Marcovina, W. Riesen, and R. Darioli
Dose-Dependent Inverse Relationship Between Alcohol Consumption and Serum Lp(a) Levels in Black African Males
Arterioscler. Thromb. Vasc. Biol., April 1, 1999; 19(4): 1075 - 1082.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. M. Grundy, G. J. Balady, M. H. Criqui, G. Fletcher, P. Greenland, L. F. Hiratzka, N. Houston-Miller, P. Kris-Etherton, H. M. Krumholz, J. LaRosa, et al.
Primary Prevention of Coronary Heart Disease: Guidance From Framingham : A Statement for Healthcare Professionals From the AHA Task Force on Risk Reduction
Circulation, May 19, 1998; 97(18): 1876 - 1887.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P. N. Hopkins, L. L. Wu, S. C. Hunt, B. C. James, G. M. Vincent, and R. R. Williams
Lipoprotein(a) Interactions With Lipid and Nonlipid Risk Factors in Early Familial Coronary Artery Disease
Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 2783 - 2792.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
R. A. Hegele, W. C. Breckenridge, J. H. Brunt, and P. W. Connelly
Genetic Variation in Factor VII Associated with Variation in Plasma Lipoprotein(a) Concentration
Arterioscler. Thromb. Vasc. Biol., September 1, 1997; 17(9): 1701 - 1706.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moliterno, D. J.
Right arrow Articles by Hobbs, H. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moliterno, D. J.
Right arrow Articles by Hobbs, H. H.

ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.